Major Depressive Disorder News and Research

RSS

Major Depressive Disorder (MDD) is a psychiatric condition characterized by depressed mood or anhedonia (significant loss of interest or pleasure). The condition affects more than 15.7 million adults and approximately 3 million adolescents (aged 13 to 17 years) in the USA each year.

Forest submits levomilnacipran NDA with FDA for treatment of major depressive disorder

Forest Laboratories, Inc. and Pierre Fabre Laboratories todayannounced that Forest has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for levomilnacipran, a serotonin norepinephrine reuptake inhibitor (SNRI) for the treatment of Major Depressive Disorder (MDD) in adults.

27 Sep 2012

Executive attention deficits in youth at risk for mood disorders

Young people with a parental history of bipolar disorder or major depressive disorder have slower reaction times on tests of executive attention than those with mentally healthy parents, US researchers report.

20 Sep 2012

Mood disorder, anxiety risk elevated in children with mood disordered parents

Children with a parental history of bipolar disorder or major depressive disorder are at increased risk for any mood or anxiety disorder, research shows.

19 Sep 2012

Trigeminal Nerve Stimulation: an interview with Dr Leon Ekchian, President and CEO of NeuroSigma

Trigeminal Nerve Stimulation (TNS) is a novel medical treatment in which mild electrical signals stimulate branches of the trigeminal nerve in order to change the activity of targeted brain regions. The trigeminal nerve is the largest cranial nerve, and provides sensation to the face and head. Because it is a large sensory nerve, the trigeminal offers a high-bandwidth pathway for electrical signals to enter the brain. The brain areas targeted by TNS are known to play key roles in seizures, mood, and attention.

14 Sep 2012

NeuroSigma's external Trigeminal Nerve Stimulation system awarded CE Certification

NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that it received CE Certification for its external Trigeminal Nerve Stimulation (eTNS) system, called the Monarch, for the adjunctive treatment of epilepsy and major depressive disorder, for adults and children 9 years and older.

5 Sep 2012

Breastfeeding may lower risk for depression in adulthood

A study published in the last issue of Psychotherapy and Psychosomatics examines the relationship between breastfeeding and onset of depression in adulthood.

5 Sep 2012

A third of depression patients convert to bipolar disorder

Around a third of patients initially diagnosed with major depressive disorder have their diagnosis changed to bipolar disorder, Polish researchers report.

8 Aug 2012

Creatine may fight major depression in women

Women battling stubborn major depression may have a surprising new ally in their fight—the muscle-building dietary supplement creatine.

7 Aug 2012

Exercise partially alleviates depression in heart failure patients

Structured exercise achieves modest reductions in depressive symptoms relative to usual care among patients with heart failure the results of a randomized-controlled trial show.

6 Aug 2012

Exercise improves mood in heart failure patients

Structured exercise achieves modest reductions in depressive symptoms relative to usual care among patients with heart failure, the results of a randomized-controlled trial show.

6 Aug 2012

Exercise reduces symptoms of depression in patients with chronic heart failure

Patients with chronic heart failure who participated in exercise training had modest reductions in symptoms of depression after 12 months, compared with usual care, according to a study in the August 1 issue of JAMA.

1 Aug 2012

Study uncovers pathways by which yoga impacts biological processes

Six months ago, researchers at UCLA published a study that showed using a specific type of yoga to engage in a brief, simple daily meditation reduced the stress levels of people who care for those stricken by Alzheimer's and dementia. Now they know why.

25 Jul 2012

First-episode schizophrenia patients show frontal white matter deficits

Results from a Brazilian study suggest that patients with a first episode of schizophrenia or schizophreniform disorder show significant white matter deficits in the middle frontal gyrus region of the brain.

17 Jul 2012

Factors linked with MDD transition to BD identified

A wide range of demographic, clinical, and environmental factors are associated with an increased risk for transition from major depressive disorder to bipolar disorder, US study results show.

10 Jul 2012

Factors linked with MDD transition to BD identified

A wide range of demographic, clinical, and environmental factors are associated with an increased risk for transition from major depressive disorder to bipolar disorder, US study results show.

10 Jul 2012

Oxytocin levels linked to medication dose, symptoms in schizophrenia

Higher doses of second-generation antipsychotics and more severe negative symptoms are associated with lower levels of oxytocin in cerebrospinal fluid among patients with schizophrenia, researchers report.

29 Jun 2012

Study examines role of specific forms of psychotherapy in anxious depression

A new study that is published in the current issue of Psychotherapy and Psychosomatics examines the role of specific forms of psychotherapy, cognitive therapy in anxious depression.

27 Jun 2012

Liability for schizophrenia linked to cognition in mood disorders

Schizotypal traits and genetic liability for schizophrenia are associated with reduced cognitive functioning in patients with mood disorders, Japanese study results show.

26 Jun 2012

Vitamin D therapy may improve symptoms of depression in women

Women with moderate to severe depression had substantial improvement in their symptoms of depression after they received treatment for their vitamin D deficiency, a new study finds. The case report series will be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston.

26 Jun 2012

Pfizer, Wyeth and PF Prism file suit against Watson over generic Pristiq

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Desvenlafaxine Succinate Extended-release Tablets, 50 mg and 100 mg.

26 Jun 2012